Skip to main content
. Author manuscript; available in PMC: 2017 Mar 28.
Published in final edited form as: J Control Release. 2016 Feb 6;226:229–237. doi: 10.1016/j.jconrel.2016.02.006

Figure 4. Validation of Ab62 scFv species cross-reactivity and binding in vivo.

Figure 4

(a) Enzymatic biotinylation of Ab62 scFv modifies the protein site-specifically, preserving the antigen binding site. (b) Ab62-biotin-125I-SA (i.e., complexes of Ab62 scFv-biotin with 125I-labeled streptavidin) bound human ECs in vitro and (c) to rat lung endothelium in vivo. Mec13-biotin-125I-SA complexes were used as controls. N = 4 rats for each group, with data shown as mean ± SD. ** indicates statistical significance (p < 0.001). Inset figure shows the lung immunospecificity index, calculated as the ratio of %ID/g of targeted (Ab62) vs. nontargeted (Mec13) SA-complexes, normalized to blood levels.